Intravenous administration of CpG7909 lipoplex enhances anti-PD1 immunotherapy by modulating the tumor microenvironment and inducing durable tumor regression.

Although IFN-γ levels were elevated in the CpG7909 lipoplex-treated group, the increase did not reach statistical significance ( p = 0.056) (Fig. 2 d), indicating a trend toward increased immune activation.

also in 111,027 other papers

Although the differences relative to the Anti-PD1 or Anti-PD1 + free CpG7909 groups did not reach statistical significance, the lipoplex-treated group demonstrated a clear trend toward improved tumor control (Fig. 6 c).

also in 19,460 other papers